[ad_1]
SEKISUI Diagnostics has introduced the Metrix® COVID/Flu Test, a molecular diagnostic tool designed to detect and differentiate SARS-CoV-2, Influenza A, and Influenza B from nasal swab samples. This test was developed in collaboration with Aptitude Medical Systems and builds on the two companies’ previous partnership, which focused on distributing the Metrix® COVID-19 Test.
The Metrix® COVID/Flu Test offers results in just 20 minutes with minimal user involvement. This makes the molecular diagnostic tool suitable for point-of-care settings such as urgent care clinics, physician offices, and remote healthcare facilities, as well as for home use.
The Metrix® COVID/Flu Test’s affordability, ease of use, and rapid turnaround time position it as a competitive option in the molecular diagnostics market. The emergency use authorization (EUA) from the FDA underscores the test’s reliability for detecting these specific viruses, though it is important to note that it has not received full FDA clearance.
Image Credit: SEKISUI Diagnostics
[ad_2]
Source link
